Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Analysis

Editor-in-Chief

ISSN (Print): 1573-4129
ISSN (Online): 1875-676X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form

Author(s): Sonali Thorat*, Rupesh Chikhale, Vanita Rode and Madhukar Tajne

Volume 15, Issue 1, 2019

Page: [61 - 66] Pages: 6

DOI: 10.2174/1573412913666171023154934

Price: $65

Abstract

Background: Capecitabine is an orally available prodrug of 5-flurouracil used in the treatment of breast cancer, metastatic colorectal cancer and stage III colorectal cancer. Various studies have reported the HPLC, HPLC-MS, MS/MS methods for estimation of capecitabine. However, till date HPTLC method for estimation of capecitabine and its validation is not reported in tablet dosage form.

Introduction: Presented study deals with the development and validation of stability indicating high performance thin layer chromatography method for the determination of Capecitabine in tablet dosage form.

Methods: The method was developed using precoated HPTLC plates with silica gel 60 F254 as stationary phase and toluene-methanol the ratio of 7.5:2.5 v/v as the mobile phase. Capecitabine (RF 0.48 ± 0.03) and its degradation products were well resolved. The wavelength selected for study was 240 nm. The method was linear in the concentration range 50–550 ng/band with a correlation coefficient of 0.994. The repeatability for six samples was 1.25% RSD. The intraday and interday precisions were 1.46-1.71%RSD and 1.31-1.67% RSD, respectively. The accuracy (recovery) was found to be in the range of 99.10-101.23% with LOD and LOQ were found to be 0.650 and 1.765 mg/band. The mean content of drug in tablet dosage form was found to be 101.51% with a % RSD of 1.20. The drug was subjected to stress conditions such as hydrolysis, oxidation, photolysis, and heat.

Results: Degradation products produced as a result of the stress conditions did not interfere with the detection of Capecitabine; therefore, the proposed technique can be considered stability-indicating. Capecitabine did not degrade under thermal and photolytic conditions but showed degradation under acidic and alkaline conditions with 15 and 11% decompositions respectively.

Conclusion: The developed method was found to be facile, simple, specific, precise, and stabilityindicating. It can be employed for the routine analysis of capecitabine in tablet dosage form.

Keywords: Capecitabine, prodrug, high-performance thin-layer chromatography, stability-indicating stress degradation, tablet dosage, anticancer drug.

« Previous Next »
Graphical Abstract

[1]
National Cancer Institute thesaurus, Version 15.11e release date 30/11/2015, Retrieved from https://ncit.nci.nih.gov/ncitbrowser/ ConceptReport.jsp?dictionary=NCI_Thesaurus& version=15.11e& ns=NCI_Thesaurus&code=C1794 Retrieval dated 13/1/2017.
[2]
Ishitsuka, H.; Shimma, N.; Horii, I. Discovery and development of novel anticancer drug capecitabine. Yakugaku Zasshi, 1999, 119, 881-897.
[3]
Miwa, M.; Ura, M.; Nishida, M. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 1998, 34, 1274-1281.
[4]
Farkouh, A.; Ettlinger, D.; Schueller, J. A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes. Antican Res., 2010, 30, 5207-5211.
[5]
Zufia, L.; Aldaz, A.; Giraldez, J. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. J. Chromatogr. B., 2004, 809, 51-58.
[6]
Montange, D.; Bérard, M.; Demarchi, M. An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma. J. Mass Spectrom., 2010, 45, 670-677.
[7]
Piórkowska, K.; Kaza, M.; Fitatiuk, J. Rapid and simplified HPLC-UV method with on-line wavelengths switching for determination of capecitabine in human plasma. Pharmazie, 2014, 69, 500-505.
[8]
Xu, Y.; Grem, J. Liquid chromatography–mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. J. Chromatogr. B., 2003, 783, 273-285.
[9]
Guichard, S.; Mayer, I.; Jodrell, D. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies. J. Chromatogr. B., 2005, 826, 232-237.
[10]
Dhananjeyan, M.; Liu, J.; Bykowski, C. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography. J. Chromatogr. A, 2007, 101, 1138-1139.
[11]
Gieschke, R.; Burger, H.; Reigner, B. Population pharmacokinetics and concentration–effect relationships of capecitabine metabolites in colorectal cancer patients. British . J. Clin. Pharmacol., 2003, 55, 252-258.
[12]
Chaigneau, L.; Royer, B.; Montange, D. Influence of capecitabine absorption on its metabolites pharmacokinetics: A bioequivalence study. Annals. Oncol., 2008, 19, 1980-1981.
[13]
ICH, Q2 (R1) Validation of Analytical Procedures: Text and methodology; In: Proceedings of the International Conference on Harmonization; IFPMA, Geneva, 2003..
[14]
ICH, Q1A (R2) Stability Testing of New Drug Substances and Products; In Proceedings of the International Conference on Harmonization; IFPMA, Geneva, 2003..
[15]
ICH, Q1B. Stability Testing: Photostability Testing of New Drug Substances and Products; In Proceedings of the International Conference on Harmonization. IFPMA, Geneva, 2003..
[16]
Boisagar, S.; Patel, H.; Patel, C.; Jayswal, U. A validated high-performance thin layer chromatography method for estimation of lornoxicam and paracetamol in their combined tablet dosage form. Pharmaceut. Methods, 2011, 2, 83-87.
[17]
Prajapati, P.; Rakholiya, A.; Bodiwala, K.; Marolia, B.; Shah, S. Stability indicating HPTLC method for estimation of dabigatran etexilate mesylate in its pharmaceutical dosage form. Eurasian J. Anal. Chem., 2017, 12, 75-86.

Rights & Permissions Print Cite
Article Metrics
27
2
© 2024 Bentham Science Publishers | Privacy Policy